• Login
    View Item 
    •   MUST-IR Home
    • Faculty of Medicine
    • Department of Nursing
    • Reseach articles
    • View Item
    •   MUST-IR Home
    • Faculty of Medicine
    • Department of Nursing
    • Reseach articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trial

    Thumbnail
    View/Open
    Main article (723.7Kb)
    Date
    2003
    Author
    Priotto, Gerardo
    Kabakyenga, Jerome
    Pinoges, Loretxu
    Ruiz, Aria
    Eriksson, Therese
    Coussement s, Frangois
    Ngambe, Tharcise
    Taylor, Walter R. J.
    Perea, William
    Guthmann, Jean-Paul
    Olliaro, Piero
    Legros, Dominique
    Metadata
    Show full item record
    Abstract
    Drug-resistant malaria is spreading in Africa. The few available drugs might be safeguarded if combined with an artemisinin derivative. We investigated the efficacy, safety, and tolerability of 2 combinations of artesunate with sulfadoxine-pyrimethamine (SP) in a mesoendemic region in Uganda with SP resis tance, from September 1999 to June 2000. In a randomized, double-blind, placebo-controlled trial, 420 children aged 6-59 months with uncomplicated Plasmodium falciparum malaria were assigned SP alone (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine) or combined with artesunate (AS; 4 mg/kg/d) for either 1 d (SPAS1) or 3 d (SPAS3). Children were followed-up for 28 d. Day 14 cure rates were 84.6% (99/117) with SPAS3 and 61.9% (73/118) with SPAS1 compared with 55.8% (86/154) with SP. Corresponding day 28 results were 74.4% (87/117) and 45.2% (52/115) compared with 40.5% (62/153). A significant improvement was obtained with the addition of 3 d, but not 1 d, of artesunate (risk ratio [RR] = 1.5, 95% CI 1.3-1.8 at 14 d and RR = 1.8, 95% CI 1.5-2.3 at 28 d). Both AS regimens achieved significantly faster parasite clearance and lower gametocyte carriage. All drug regi mens were well tolerated, but SP alone was ineffective. Treatment efficacy improved with SPAS3 but the cure rate at day 28 was modest. The combinations were well tolerated and safe. In areas where SP resistance is prevalent other combinations should be considered.
    URI
    http://ir.must.ac.ug/xmlui/handle/123456789/1722
    Collections
    • Reseach articles [74]

    MUST-IR
    Contact Us | Send Feedback

    Atmire NV
     

     

    Browse

    All of MUST-IRCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    MUST-IR
    Contact Us | Send Feedback

    Atmire NV